InflaRx (IFRX) EBITDA (2016 - 2026)
InflaRx (IFRX) posted EBITDA of -$8.4 million for Q1 2026, down 120.48% sequentially from $41.2 million in Q4 2025, and up 38.31% YoY from -$6.1 million in Q1 2025.
InflaRx (IFRX) EBITDA (2016 - 2026) Analysis & Trends
InflaRx has reported EBITDA for 11 years, with the latest figure at -$8.4 million in Q1 2026.
- Quarterly EBITDA rose 38.31% year-over-year to -$8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 870.36% YoY) and the FY2025 annual result came in at -$54.52, up 4.97% from the prior year.
- EBITDA retreated to -$8.4 million in Q1 2026 per IFRX's latest filing, from $41.2 million in the prior quarter.
- Over five years, EBITDA peaked at $46.2 million in Q4 2024 and troughed at -$16.9 million in Q3 2024.
- A 5-year average of -$4.6 million and a median of -$11.1 million in 2025 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 422.78% in 2024, down 119304982.7% in 2024.
- Over 5 years, EBITDA stood at -$7.9 million in 2022, then tumbled by 82.27% to -$14.3 million in 2023, then surged by 422.78% to $46.2 million in 2024, then declined by 10.83% to $41.2 million in 2025, then plunged by 120.48% to -$8.4 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$8.4 million, $41.2 million, and -$11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | InflaRx | 137.60 Mn | -46.65 Mn | 2.74 Bn | -8.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.44 Mn |
| Dec 31, 2025 | 41.21 Mn |
| Sep 30, 2025 | -11.08 Mn |
| Jun 30, 2025 | -14.62 Mn |
| Mar 31, 2025 | -13.68 Mn |
| Dec 31, 2024 | 46.21 Mn |
| Sep 30, 2024 | -16.87 Mn |
| Jun 30, 2024 | -16.58 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -14.32 Mn |
| Sep 30, 2023 | -12.14 Mn |
| Jun 30, 2023 | -10.73 Mn |
| Mar 31, 2023 | -11.37 |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -8.67 Mn |
| Jun 30, 2022 | -1.16 Mn |
| Mar 31, 2022 | -16.68 Mn |
| Dec 31, 2021 | -14.87 Mn |
| Sep 30, 2021 | -15.02 Mn |
| Jun 30, 2021 | -16.84 Mn |